Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine ? the REBUILD-1 Study

CGAS_Rebuild_1

Phase: III
Clinicaltrials.gov ID: NCT03432286

What is the goal of the study?

This study is being done to see how safe galcanezumab is and how well it will work to help reduce the number of episodic migraines in children and adolescents.

Who can participate in the study?

This study might be a good fit for you if you: You are 6 to 17 years old at Visit 1 You have a diagnosis of migraine with or without aura, with a history of migraine headaches of at least 6 months prior to Visit 1 Within the 2 months prior to Visit 1, have a history of 4-14 headache days per month, of which at least 4 are migraine headache days, and with at least 2 migraine attacks per month

Study Team:

PI (Study Doctor): Heidi Blume
Study Team Member: Mikaela Gatterman, Mikaela.Gatterman@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.